Panic Developments – An Interesting Editorial by Donald F. Klein in the Revista Brasileira de Psiquiatria

Revista Brasileira de Psiquiatria 2012;34(Supl1):S01-S04

Panic Developments

This editorial permits personal conclusions and questions, hoping to stimulate relevant research. Klein, in 1959, serendipitously found that imipramine blocked the apparently spontaneous panic attack in non-depressed inpatients, later considered agoraphobic.Later it was found that these specific anti-panic drugs blocked lactate challenges, although low potency benzodiazepines and beta-blockers did not. Also, panic patients with early onset, frequently had a history of severe separation anxiety disorder, often manifested as school phobia. A series of usually post-pubertal panics led to severe chronic distress marked by fearful anticipation that the next panic would cause death or insanity. Avoiding situations (bridges, tunnels, freeways etc.) where help could not be readily obtained if panic reoccurred led to extensive travel restrictions and demands to be accompanied. These avoidances were misinterpreted as phobias, since there was no fear of cars or bridges per se. Family exhaustion led to psychoanalytic psychiatric hospitalization.1 In 1967, Pitts found, in placebo-controlled studies that intravenous sodium lactate in patients with spontaneous panics, then considered anxiety neurosis, could regularly cause such attacks. Further, other stressful infusions, such as EDTA, did not elicit panics, ruling out conditioning as a feasible alternative view. Later studies found inhaled 5%-7% carbon dioxide was similar to IV lactate as a panicogen, while willful room air hyperventilation was an uncommon panicogen. This contradicted the hyperventilation theory of panic disorder. Such panic reactions rarely occurred in patients with other anxiety disorders, other psychopathological states or normal subjects, except strangely, in women with severe chronic premenstrual syndrome.Groundbreaking therapies derived from this program. Panic disorder and agoraphobia were now quite treatable outpatient conditions, although unfortunately DSM-III distorted agoraphobia’s definition by simply choosing six frequent avoidances as criteria, while ignoring their common role in preventing flight to help, as well as the utility of a companion for travel.

The lactate study initiated by Jean Endicott and Wilma Harrison led to SSRI treatment for PMS. Rachel Klein demon- strated the value of imipramine and counseling in the treatment of refractory Separation Anxious Disorder (mislabeled school phobia), laying the groundwork for SSRI treatment of children.

Since panic disorder and agoraphobia were stipulated in DSM-III, an enormous proliferation of studies attempted to clarify this area. Although the panic attack seemed fear like, there were incongruent features. Mandel Cohen (1940) showed such attacks were usually associated with marked air hunger, which was not characteristic of external danger induced fear. Further, remarkably, both clinical and challenge studies of panic disorder did not elicit the emergency reaction of hypothalamic-pituitary-adrenal (HPA) release. Thus, panic attack was not fear or due to a hypersensitive fear system.It was hypothesized that, rather than a generalized HPA alarm system responsive to all dangers, many separate alarm/ response mechanisms had evolved, over evolutionary time, to deal with recurrent distinct dangers. Such an alarm/response system dealt with the recurrent danger of suffocation, whose affective and behavioral response system must act quickly to prevent anoxic brain damage. Hypersensitivity of that system to signals of possible suffocation could result in panic and escape. Conversely, carbon dioxide insensitivity existed in congenital central hypoventilation syndrome. Preter and Klein’s controlled lactate study in normal subjects found a panic like tidal volume increase if naloxone anteceded intravenous lactate. This was consonant with the hypothesis that an inhibited endogenous opioidergic system caused hypersensitivity of the suffocation alarm/response system.2,3
[Full text here]
Posted in Affective Neuroscience, Fifth Avenue Concierge Medicine, Health, keto, News | Tagged , , , , |

Ben Goldacre: What doctors don’t know about the drugs they prescribe | Video on TED.com

Ben Goldacre: What doctors don’t know about the drugs they prescribe | Video on TED.com

via Ben Goldacre: What doctors don’t know about the drugs they prescribe | Video on TED.com.

Posted in Complementary - Alternative Medicine, Fifth Avenue Concierge Medicine, Forensic Neuropsychiatry, Health, keto, Video | Tagged , , |

Cancer chemopreventive effects and cytotoxic activities of the triterpene acids from the resin of Boswellia carteri.

Biol Pharm Bull. 2006 Sep;29(9):1976-9.

Cancer chemopreventive effects and cytotoxic activities of the triterpene acids from the resin of Boswellia carteri.

Akihisa T, Tabata K, Banno N, Tokuda H, Nishimura R, Nakamura Y, Kimura Y, Yasukawa K, Suzuki T.

Source

College of Science and Technology, Nihon University, Tokyo, Japan. akihisa@chem.cst.nihon-u.ac.jp

Erratum in

Biol Pharm Bull. 2006 Dec;29(12):2536. Nishihara, Reiko [corrected to Nishimura, Reiko].

Abstract

Fifteen triterpene acids, viz., seven of the beta-boswellic acids (ursane-type) (1-7), two of the alpha-boswellic acids (oleanane-type) (8, 9), two of the lupeolic acids (lupane-type) (10, 11), and four of the tirucallane-type (12-14, 16), and two cembrane-type diterpenes (17, 18), isolated from the MeOH extract of the resin of Boswellia carteri (Burseraceae), together with a triterpene acid 15 (the acetyl derivative of 14), were examined for their inhibitory effects on the induction of Epstein-Barr virus early antigen (EBV-EA) by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells and on activation of (+/-)-(E)-methyl-2[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitrogen oxide (NO) donor, and cytotoxic activities against three human neuroblastoma cell lines, IMR-32, NB-39, and SK-N-SH in vitro. On evaluation against the EBV-EA activation induced by TPA, seven compounds, 2, 10, 11, and 13-16, showed potent inhibitory effects on EBV-EA induction. Upon evaluation against activation of NOR 1, five compounds, 7, 13, and 14-16, showed potent inhibitory effects. Further, fifteen compounds, 1-7, 9-11, 13-15, 17, and 18, exhibited potent cytotoxic activities with IC(50) values of 4.1-82.4 muM against all of the three human neuroblastoma cells tested.

PMID:

16946522

[PubMed – indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

LinkOut – more resources

via Cancer chemopreventive effects and cytotoxic… [Biol Pharm Bull. 2006] – PubMed – NCBI.

Posted in Fifth Avenue Concierge Medicine, Forensic Neuropsychiatry, Health, keto, Psychiatry/Neurology | Tagged , , |

Selenium and the thyroid: a close-knit connection.

J Clin Endocrinol Metab. 2010 Dec;95(12):5180-8. doi: 10.1210/jc.2010-0191. Epub 2010 Sep 1.

Selenium and the thyroid: a close-knit connection.

Source

Endocrine Unit, Evgenidion Hospital, University of Athens, 20 Papadiamantopoulou Street 115 28 Athens, Greece. ledunt@otenet.gr

Abstract

CONTEXT:

The recent recognition that the essential trace element selenium is incorporated as selenocysteine in all three deiodinases has decisively confirmed the clear-cut link between selenium and thyroid function. It has additionally been established that the thyroid contains more selenium than any other tissue and that selenium deficiency aggravates the manifestation of endemic myxedematous cretinism and autoimmune thyroid disease.

EVIDENCE ACQUISITION:

Clinical reports as well as a large number of biochemical articles linking selenium to thyroid have been considered. Interventional, prospective, randomized, controlled studies, including large observational studies, supplementing selenium in autoimmune thyroid disease, together with review articles published in Medline and Pubmed have undergone scrutiny. The methodological differences and variety of results emerging from these trials have been analyzed.

EVIDENCE SYNTHESIS:

Evidence in support of selenium supplementation in thyroid autoimmune disease is evaluated, the results herein presented demonstrating the potential effectiveness of selenium in reducing the antithyroid peroxidase titer and improving the echostructure in the ultrasound examination. However, considerable discord remains as to who should comprise target groups for selenium treatment, who will most benefit from such treatment, the precise impact of the basal antithyroid peroxidase level, and the effect of disease duration on the treatment outcome. Clearly, further in-depth studies and evaluation are required concerning the mechanism of action of selenium as well as the choice of supplements or dietary intake.

CONCLUSIONS:

Maintenance of “selenostasis” via optimal intake not only aids preservation of general health but also contributes substantially to the prevention of thyroid disease.

PMID:
20810577
[PubMed – indexed for MEDLINE]

Free full text

Posted in Fifth Avenue Concierge Medicine, Health, keto, Psychiatry/Neurology | Tagged |

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

Arch Neurol. 2012 Feb;69(2):183-90. doi: 10.1001/archneurol.2011.1426. Epub 2011 Oct 10.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, Simon JH; Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Investigators.

Collaborators (24)

Source

Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, KS 211, Boston, MA 02215, USA. rkinkel@bidmc.harvard.edu

Abstract

OBJECTIVE:

To determine whether immediate initiation of treatment at the time of a clinically isolated syndrome in patients at high risk for clinically definite multiple sclerosis alters disease course over 10 years.

DESIGN:

Prospective follow-up study.

SETTING:

Twenty-four Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) sites in the United States and Canada.

PARTICIPANTS:

A total of 81 patients originally randomly assigned to receive intramuscular interferon beta-1a (the immediate-treatment group) and 74 patients originally randomly assigned to receive placebo (the delayed-treatment group). All patients were from CHAMPS.

INTERVENTION:

For the immediate-treatment group, treatment was initiated within a month after the onset of a clinically isolated syndrome, and for the delayed-treatment group, treatment was initiated a median of 30 months (interquartile range, 24-35 months) after CHAMPS randomization.

MAIN OUTCOME MEASURES:

Rate of developing clinically definite multiple sclerosis, annualized relapse rate, disease course classification, disability measures, and magnetic resonance imaging measures.

RESULTS:

The immediate-treatment group showed a lower 10-year rate of clinically definite multiple sclerosis (unadjusted hazard ratio, 0.64 [95% CI, 0.48-0.87]; P = .004) and a lower annualized relapse rate between years 5 and 10 (P = .03). There was no differential effect on disability, magnetic resonance imaging T2-weighted lesions, or the proportion of patients developing progressive disease at 10 years. Few patients reached the Expanded Disability Status Scale milestone scores of 4.0 or greater (9% of patients) or 6.0 or greater (6% of patients).

CONCLUSIONS:

Immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome in high-risk patients reduces relapse rates over 10 years but does not improve disability outcomes compared with a control group that also initiated therapy relatively early in the disease course.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT00179478.

PMID:

21987393

[PubMed – indexed for MEDLINE]

Related citations

via 22 selected items – PubMed – NCBI.

Posted in Fifth Avenue Concierge Medicine, Health, keto, Psychiatry/Neurology | Tagged , , |